Efficacy, safety and mechanism of action of modified-release prednisone in rheumatoid arthritis
Authors:
Open Access
- 21 March 2012
- journal article
- research article
- Published by SAGE Publications in Therapeutic Advances in Musculoskeletal Disease
- Vol. 4 (3) , 159-166
Abstract
Glucocorticoids (GCs) provide a powerful and widely used anti-inflammatory and disease-modifying therapy for rheumatoid arthritis (RA). However, concerns about adverse effects are driving efforts to find ‘safer’ GC or GC analogues. One novel approach has been to change the timing of GC delivery, targeting the early hours of the morning to suppress the observed circadian peak in interleukin-6 (IL-6). The CAPRA-1 study has shown that this produces a clinically useful beneficial improvement in morning stiffness and mechanistic studies have shown that this correlates with a strong suppression of the IL-6 early morning peak. With no obvious additional adverse reactions, this improvement in the therapeutic ratio offers additional treatment options in RA, and perhaps in other inflammatory diseases that show circadian variation in symptoms.Keywords
This publication has 46 references indexed in Scilit:
- Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritisAnnals of the Rheumatic Diseases, 2010
- Circulating cytokines in active polymyalgia rheumaticaAnnals of the Rheumatic Diseases, 2010
- Characterization of ZK 245186, a novel, selective glucocorticoid receptor agonist for the topical treatment of inflammatory skin diseasesBritish Journal of Pharmacology, 2009
- Modified-Release Hydrocortisone to Provide Circadian Cortisol ProfilesThe Journal of Clinical Endocrinology & Metabolism, 2009
- Selective amplification of glucocorticoid anti-inflammatory activity through synergistic multi-target action of a combination drugArthritis Research & Therapy, 2009
- Overnight variations in cortisol, interleukin 6, tumour necrosis factor α and other cytokines in people with rheumatoid arthritisAnnals of the Rheumatic Diseases, 2009
- Low‐dose prednisolone in addition to the initial disease‐modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: A two‐year randomized trialArthritis & Rheumatism, 2005
- COBRA combination therapy in patients with early rheumatoid arthritis: Long‐term structural benefits of a brief interventionArthritis & Rheumatism, 2002
- The timing of glucocorticoid administration in rheumatoid arthritisAnnals of the Rheumatic Diseases, 1997
- Circadian rhythm of serum interleukin-6 in rheumatoid arthritis.Annals of the Rheumatic Diseases, 1994